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ABSTRACT 
Popular wisdom holds that antioxidants protect against cancer because they 
neutralize reactive oxygen species (ROS) and other free radicals which can 
otherwise cause cancer by damaging DNA. This has been the rationale behind 
many clinical trials with antioxidants, which in most cases failed to show a 
beneficial effect and in others even increased cancer incidence. Our group 
believes that these inconsistencies can be explained by the idea that 
antioxidants have opposite effects on tumor initiation and progression, and 
that tumor cells benefit from low ROS levels which is facilitated by 
antioxidant supplementation.  In this thesis we describe the effects of two 
widespread antioxidants, N-acetylcysteine and vitamin E, on malignant 
melanoma progression, a cancer known to be sensitive to redox alterations, 
using a transgenic mouse model and a panel of human cell lines. Because 
strong evidence links mitochondria-associated ROS to tumor progression, 
we also define the impact of targeting mitochondrial ROS on malignant 
melanoma and lung cancer progression. The results show that dietary 
antioxidant supplementation increases metastasis in malignant melanoma, and 
that this is dependent on new glutathione synthesis and activated RHOA.  
The data also indicates that mitochondria-targeted antioxidants do not inhibit 
cancer progression. These results suggest that cancer patients and people 
with high risk of developing cancer should avoid the use of antioxidant 
supplements. 
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SAMMANFATTNING PÅ SVENSKA 
Det är allmänt vedertaget att antioxidanter skyddar mot cancer eftersom de 
neutraliserar reaktiva syreföreningar (ROS) och andra fria radikaler som 
annars kan orsaka cancer genom att skada DNA. Detta har varit grunden till 
många kliniska prövningar med antioxidanter, vilka i de flesta fall misslyckades 
med att visa en fördelaktig effekt och där vissa även ökade cancerincidensen. 
Vår grupp anser att dessa inkonsekvenser kan förklaras av att antioxidanter 
har motsatta effekter på tumörinitiering och progression, och att 
tumörcellerna drar nytta av låga ROS-nivåer, vilket underlättas av 
antioxidanttillskott. I denna avhandling beskrivs effekterna av två väl använda 
antioxidanter, acetylcystein och E-vitamin, på malignt melanomprogression, 
en cancer som är känd för att vara känslig för redoxförändringar, genom att 
använda en transgen musmodell och en panel av humana cellinjer. Eftersom 
starka bevis kopplar mitokondrie-associerade ROS till tumörprogression 
definierar vi också effekten av att rikta antioxidanter specifikt mot 
mitokondriella ROS på malignt melanom och lungcancerprogression. 
Resultaten visar att kosttillskott av antioxidanter ökar metastasering i malignt 
melanom och att detta är beroende av ny glutationsyntes och aktiverad 
RHOA. Uppgifterna indikerar också att mitokondrie-riktade antioxidanter 
inte hämmar cancerprogression. Dessa resultat tyder på att cancerpatienter 
och personer med hög risk att utveckla cancer bör undvika användning av 
kosttillskott som innehåller antioxidanter.
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ABBREVIATIONS 
BSO Buthionine sulfoximine 
COPD Chronic obstructive pulmonary disease 
DHE Dihydroethidium 
DHR Dihydrorodamine 
DNA Deoxyribonucleic acid 
EGF Epidermal growth factor 
ETC Electron transport chain 
GFP Green fluorescent protein 
roGFP Redox-sensitive green fluorescent protein 
GRX Glutaredoxin 
GSH Reduced glutathione 
GSSG Oxidized glutathione 
H2DCF 2´,7´-dihydrodichlorofluorescein 
  
4-HT 4-hydroxytamoxifen 
MAPK Mitogen-activated protein kinase 
NAC N-acetylcysteine 
NOX NAD(P)H oxidase 
PDGF Platelet-derived growth factor 
PRX Peroxiredoxin 
PTP Protein tyrosine phosphatase 
ROCK Rho-associated protein kinase 
ROS Reactive oxygen species 
SOD Superoxide dismutase 
dTPP Decyltriphenylphosphonium 
TRX Thioredoxin 
UV Ultra-violet 
  
  
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
If I had a world of my own, everything would be nonsense. Nothing would be what 
it is, because everything would be what it isn't. And contrary wise, what is, it 
wouldn't be. And what it wouldn't be, it would. You see? – Lewis Carroll 
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ANTIOXIDANTS AND ROS: REACHING 
FOR THE GOLDEN MEAN 
The concept of balance as a centerpiece of harmony and wellbeing is common 
to most societies and cultures. And thus we read of virtue and aurea 
mediocritas or Golden Mean from classic Greek philosophers like Aristotle, 
the Middle Path from Buddha, moderation in all monotheistic religions, and 
we even encounter the notion of “lagom” in the everyday Swedish life. 
This idea is but a reflection of life itself where organisms adapt to their 
environment and find stability to exist, and where cells regulate their internal 
state in search for an equilibrium or homeostasis. This homeostasis however, 
is not static and it is subjected to necessary fluctuations; hence, there is a 
need for systems with the ability to detect these alterations in the equilibrium 
and counteract the extremes.   
An example of environmental adaptation would be the evolutionary selective 
pressure occurred during the “Great Oxidation” around 2.4 billion years ago, 
which favored life adjusted to the presence of oxygen [1, 2]. Although a toxic 
agent, oxygen increased the production of energy in aerobic organisms by 
becoming the final electron acceptor in the electron transport chain (ETC), 
and consequently some oxygen biproducts were generated during the 
process [3]. These agents are known as reactive oxygen species (ROS) 
because they have the capability to interact with other molecules and alter 
their oxidative status and their function [4]. Upon excessive activity of these 
ROS, a situation known as oxidative stress, and in order to reach back to 
homeostasis, cells have developed antioxidant defenses that neutralize ROS 
by giving back the electrons taken [5, 6]. These antioxidants can be produced 
endogenously, but they can also be supplied in the diet [7]. 
  
ROS were initially regarded as purely damaging agents, the toll we paid for 
using oxygen to produce more energy. But thanks to advances in the redox 
field, in charge of studying reduction-oxidation reactions, we now know that 
they also regulate a wide variety of cell signaling events that are essential to 
the normal function of cells and organisms [8]. Therefore, understanding 
their role in health and disease is of great interest in medicine.    
ROS CAN CAUSE CANCER 
As previously mentioned ROS can modify proteins and DNA and therefore 
regulate signaling pathways. For example, they can inhibit or activate them by 
reversible oxidation of cysteine residues in proteins. The advantage of this 
type of regulation is that ROS have a short half-life and are able to easily 
diffuse across membranes, making available both intra- and intercellular 
control [9]. Examples of ROS mediated signaling are the response to growth 
factors, such as EGF or PDGF, which upon binding to their receptors increase 
ROS production through NAD(P)H oxidases (NOXes) located in the cellular 
membrane or the response to steroid hormones, which can change 
intracellular levels of calcium and dephosphorylate cytochrome c oxidase, 
thereby increasing the mitochondrial membrane potential and consequently, 
the production of superoxide (O2· ) [10-12]. Conversely, antioxidants can 
inhibit growth factor signaling. One way in which ROS regulate these signaling 
cascades is the inhibition of neighboring phosphatases. Hydrogen peroxide 
(H2O2) is a well-known inhibitor of protein tyrosine phosphatases (PTPs), 
such as RPTP-α, PTP-1B, SHP-2 and MKPs. ROS can also inhibit antioxidant 
proteins that are normally bound to kinases, like thioredoxins (Trx) or 
peroxiredoxins (Prx)[13]. 
Increased ROS production has been observed in a variety of cancers [14, 15]. 
This exacerbated production can come from NOXes in the cellular 
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membrane, the ETC in the mitochondria or from xanthine oxidase [6]. A 
decrease in endogenous antioxidant activity can also increase ROS content 
in the cell. The exact mechanisms that trigger the uncontrolled production 
of ROS remain largely unknown. Nevertheless, altered ROS levels can cause 
mitochondrial and genomic DNA damage.  It also affects the regulation of 
transcription factors that are involved in apoptotic signaling by regulating 
their DNA binding activity. For instance, the tumor suppressor p53 requires 
its reactive cysteines to be reduced in order to bind to DNA [16]. 
Since ROS can modify proteins and DNA, they can cause the formation of 
protein and DNA adducts, that in turn favor the propagation of mutations in 
the highly proliferative cancer environment [17, 18]. The formation of these 
adducts can affect gene expression by interfering with methyltransferases and 
producing hypomethylation of promoters, such as those of oncogenes [19, 
20]. Combined with the mutational silencing of tumor suppressor genes, 
there is no question that ROS can contribute to carcinogenesis [21]. 
ROS LOCALIZATION AFFECTS THEIR ROLE 
Mitochondria largely contribute to the production of ROS in the cells; in fact, 
they are the major source due to the production of O2· in the ETC from 
complexes I, II and III [3]. The O2· produced is taken care of by the 
antioxidant enzymes superoxide dismutases (SODs) and rapidly turned into 
H2O2 [22]. This mitochondrial-associated H2O2 can diffuse from the 
mitochondria into the cytosol and the extracellular environment and trigger 
signaling pathways [9]. In addition to cell signaling, mitochondrial ROS 
contribute to carcinogenesis by mutating mitochondrial DNA (mtDNA). This 
mtDNA is susceptible to mutations because of its proximity to the source of 
ROS, lower level of histones and limited proofreading [23-26]. Mutations in 
the ETC have been reported in many forms of cancer [27, 28]. 
  
Hence, cancer cells could use mitochondrial ROS production to their 
advantage [29]. Along those lines, several mitochondria-targeting antioxidant 
compounds have been developed and some promising results have been 
reported [30-32]. However, their impact on endogenous mouse models of 
cancer with an intact immune system has yet to be evaluated. 
ANTIOXIDANT SUPPLEMENTS AFFECT CELL 
SIGNALING BY TARGETING ROS 
As presented so far, the dual character of ROS, cell signaling molecules vs 
damaging agents, requires some fine tuning to keep cellular balance. It has 
also been shown that high oxidative stress levels correlate with malignant 
progression. Thus it was thought that antioxidant supplementation would 
counteract the damaging effects of ROS and promote a healthy cellular state. 
In addition, several epidemiological studies show an inverse correlation 
between cancer and antioxidant-rich diets [33]. 
To that end, numerous clinical trials have been conducted to test whether 
antioxidant supplementation could be used to fight and prevent cancer. But 
the results are somewhat mixed and it would seem that general conclusions 
cannot be drawn. The effects varied depending on the population, the type 
of cancer and the type of antioxidant used. For instance, the Linxian Nutrition 
Intervention Trial showed a decrease in gastric cancer incidence for 
participants who were supplemented with beta-carotene, vitamin E and 
selenium, but not with retinol and zinc, riboflavin and niacin, or vitamin C and 
molybdenum [34, 35]. However, the protective effect of beta-carotene, 
vitamin E and selenium was lost after 10 years post-intervention and 
increased risk for esophageal cancer was observed in participants who were 
55 years old or above at the time of inclusion [36]. In an independent study 
where Finnish male smokers were given alpha-tocopherol and beta-carotene 
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(ATBC trial), higher incidence of lung cancer was observed in the beta-
carotene treated group [37, 38]. The results were additionally confirmed in 
another large trial involving men and women at risk of developing lung cancer 
who were given beta-carotene and retinol (CARET trial); the trial had to be 
prematurely stopped due to significantly higher incidence and death rate in 
the antioxidant-supplemented group [39]. In a third study where apparently 
healthy women were given beta-carotene to assess its usefulness in 
preventing cancer and cardiovascular diseases, no harm nor benefit was 
observed [40]. In another large trial where the effects of selenium and vitamin 
E on prostate cancer prevention were assessed (SELECT trial) no significant 
differences were seen at first between treatment groups. However a 
statistically significant increase in tumor incidence was later observed in the 
vitamin E treated group [41, 42]. 
These inconsistencies are perhaps a result of a vague scientific question: “are 
antioxidants beneficial in fighting cancer?” which we think should be split into 
two different ones: 
1. Can antioxidants prevent tumor initiation? 
2. Do antioxidants hinder tumor progression? 
The answer to these questions is not an easy one. Tumor cells do have 
elevated levels of ROS in comparison to normal cells, but they are also 
vulnerable to further increases, and therefore are dependent on the use of 
antioxidant defenses. In addition, decreases in reduced glutathione (GSH) and 
increases in ROS have been shown to delay cell cycle progression through 
G1 & S phases and led to G2 cycle arrest [43]. Nonetheless, the metabolic 
plasticity of cancer cells allows them to adjust pathways to ensure the supply 
of antioxidant molecules and regulate multiple antioxidant enzymes [44, 45].  
  
CHOOSING CANCER MODELS TO DEFINE 
EFFECTS OF ANTIOXIDANTS ON CANCER 
Melanoma is the deadliest form of skin cancer and its prevalence has 
increased over the past decades [46, 47]. It can develop anywhere in the body 
and most commonly does in the skin (cutaneous melanoma). However, it is 
the metastases that arise from the primary skin tumor which determine 
patient prognosis and survival [48-50]. 
Our current knowledge and understanding of the genetic changes present in 
melanoma is vast, but the molecular mechanisms that trigger and regulate the 
progression of the disease remain largely unknown [51]. Some oncogenic 
mutations have been well described; For instance, the BRAF p.V600E mutation 
that leads to the activation of the mitogen-activated protein kinase (MAPK) 
pathway is present in roughly 50% of all cutaneous melanomas. Another 
classical melanoma oncogene is NRAS, which is found mutated in 15-20% of 
melanomas; In addition to activating the MAPK pathway, oncogenic NRAS also 
triggers the phosphatidyl-inositol 3-kinase (PI3K) pathway [52, 53]. However, 
expression of mutant BRAF alone does not progress into melanoma unless 
accompanied by other events [54], such as loss or alteration of tumor 
suppressors like PTEN or CDKN2A [55]. 
The primary identified mutagen in malignant melanoma is UV light exposure, 
but it does not account for the driving mutations that regulate known 
oncogenes in melanoma at the molecular level, leaving room for other 
processes such as oxidative stress to have an important role in the 
development of the disease [56, 57]. In addition, the skin can be exposed to 
antioxidant supplementation from different sources, such as topical and 
dietary [58]. 
Lung cancer has also caught the attention of the antioxidant field. Being the 
deadliest and most common form of cancer, it is not strange that one of the 
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largest clinical trials on antioxidant supplementation ever conducted assessed 
their efficacy in preventing it. Although its incidence among men has declined 
over the years, it is still the leading cause of cancer death among this gender 
[59]. 
The use of tobacco is the main risk factor associated with the disease [59], 
and longtime smokers are at high risk of developing chronic obstructive 
pulmonary disease (COPD) [60, 61]. To those affected, N-acetylcysteine 
(NAC) is often prescribed as a mucolytic to facilitate respiration.  
In order to evaluate the impact of antioxidant supplementation and redox 
modulation on these forms of cancer, we need to make use of specific 
research tools. 

  
RESEARCH METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
Climate is what we expect, weather is what we get. – Mark Twain 
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THE MOUSE AS A RESEARCH TOOL 
Since the times of Ancient Greece, scientists have used animal 
experimentation to study and understand the complexity of life and biological 
processes. As early as in the 4th century BC, Aristotle observed differences 
in the anatomical content and placement of organs across species through 
dissections, and Erasistratus was the first to document experiments on living 
organisms. Science and medicine have been able to develop to their current 
state thanks to the use of animal models. These organisms have offered the 
possibility of researching questions that were relevant to another species 
without direct intervention, and they have contributed to the validation of 
the scientific method in multiple disciplines [62]. However, the model chosen 
to answer to a specific physiological or pathological question should be 
carefully considered and should be relevant to the research problem at hand 
[63]. 
For this theis, I used one particular and well-known model organism to 
understand and monitor key events in cancer progression: Mus musculus, 
commonly known as the house mouse. 
Humans and mice have shared habitats since about 12,000 years ago, by the 
time of the Neolithic Revolution. It is not surprising then that these animals 
were picked as research models in the early stages of science. They are small, 
easy to breed, strains can be highly standardized through inbreeding, and their 
genetic mutations often represent human disease. 
MICE ARE VALUABLE IN CANCER RESEARCH 
Given that around 99% of the mouse genes have a human homologue, we 
can model a large variety of human pathologies by altering the mouse genome 
[64]. Additionally, although a rare event in wildlife, every mouse tissue is 
  
potentially subjected to the development of neoplastic events, just like their 
human counterparts. In order for that to happen, two types of genes can be 
manipulated: tumor suppressor genes (loss of function) and oncogenes (gain 
of function) [65].   
THE CRE-LOXP SYSTEM ALLOWS FOR GENOME 
EDITING 
One of the most common methods used to modify genes is the Cre-loxP 
technique, which relies on the use of the bacteriophage P1 cyclic recombinase 
(Cre) which recognizes DNA sequences called locus of crossing over (loxP). 
The loxP sites consist of 34 base pair (bp) long DNA fragments formed by 
two 13 bp inverted repeats separated by an 8 bp spacer region. The enzyme 
Cre cleaves sequences of DNA flanked by two loxP sites with the same 
orientation, and the resulting cleaved sequence is excised in a circular loop 
of DNA. The expression of Cre can be regulated temporally and/or spatially 
by exogenous Cre expressing vectors (plasmid or viral particles) or by 
inserting Cre behind tissue-specific promoters. 
A MOUSE MODEL TO STUDY METASTASIS 
With the aim of studying the effects of antioxidant supplementation on 
metastasis, we used the Braf CA/+ Pten f/f Tyrosinase-Cre (BPT) mouse model of 
malignant melanoma. This model is used in both paper I and II. 
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The BPT mice conditionally express oncogenic mutant BrafV600E and loose 
expression of Pten. The conditional Braf transgene expresses normal BRAF 
until activated by Cre, upon which wiltype exons 15-18 and a STOP cassette 
flanked by loxP sites are excised and replaced by a mutant exon 15 followed 
by wildtype exons 16-18. Additionally, both alleles of the tumor suppressor 
Pten have their exon 5 flanked by loxP sites, which leads to the expression of 
a non-functional PTEN protein when cleaved by Cre [66]. In this model the 
expression of Cre is spatially limited to melanocytes and some cells of the 
central nervous system, as it falls under the control of the Tyrosinase 
promoter, which regulates the expression of the skin pigment melanin [67, 
68].  
Figure 1. Genetic strategy to generate mice with malignant melanoma. After painting the skin 
of 2 days-old pups with 4-HT, the mice express mutant BRAF and inactive PTEN in 
melanocytes, which will lead to the formation of skin tumors and eventually metastases.  
  
By painting the right flank of the animals at postnatal day 2 with 4-
hydroxytamoxifen (4-HT), Cre is induced in melanocytes and thus mutant 
protein BRAF is expressed and PTEN is lost; all of which leads to the 
formation of skin tumors that eventually metastasize to regional lymph nodes 
and in some cases lungs. Despite recapitulating most of the events leading to 
the development of the disease in humans, this model is limited by the fact 
that the mice often come to a humane endpoint due to the size of the primary 
tumor and not due to the metastatic burden, which is the leading cause of 
death in humans. 
THE KRASLSL MODEL RECAPITULATES EVENTS IN 
HUMAN LUNG CANCER 
To analyze the effects of mitochondria-targeted antioxidants on tumor 
proliferation, we used a mouse model of lung cancer in paper II. 
In this model, the expression of the oncogenic Kras allele, KrasLSL-G12D, is 
controlled by exogenous Cre expressing virus which can be delivered by 
intratracheal instillation directly to the lungs or inhaled through the nose; in 
this study we used nasal inhalation of adenovirus. The mice carry a Kras allele 
with a LoxP flanked STOP cassette (LSL) followed by an activating KrasG12D 
mutation, which results in a null mutation. Without Cre expression the mice 
only produce one copy of wildtype K-RAS and are unaffected; with Cre 
expression, the STOP cassette is cleaved and mice express one copy of K-
RASG12D, which is enough to induce disease. 
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Figure 2. Genetic strategy to generate mice with KRAS-induced lung cancer. After inhaling 
adenovirus into the lungs, mice will express one copy of wildtype Kras plus one copy of mutant 
Kras, which is enough to induce the development of tumors in the lungs.  
The consequent activation of the oncogene in the lung epithelium leads to 
increased proliferation and progression to atypical adenomatous hyperplasia, 
adenomas and, finally, adenocarcinomas [69, 70]. 
ETHICAL CONSIDERATIONS ARE NEEDED 
WHEN WORKING WITH ANIMAL MODELS 
Even though animal experimentation has led to enormous advances in the 
field of scientific medicine, it has been accompanied since its origins by a 
growing criticism of the use of animals in science. These concerns were 
aggravated after the publication of Darwin´s theory of evolution, which made 
many question the line that separated animals and humans and prompted the 
creation of societies against animal cruelty [71]. 
  
Nevertheless, in comparison to other industries where animals are exploited 
for human benefit, such as farming, the use of animals in experimental 
research is tightly regulated and controlled at several levels. 
All animal experiments performed during the development of this thesis were 
evaluated and approved by the Research Animal Ethics Committee in 
Gothenburg, and all researchers involved strived to follow the 3Rs principle.    
ANALYZING ROS IN CELLS: WHEN AND 
WHERE? 
Contrary to popular belief, redox couples are not found in thermodynamic 
equilibrium in cells; they vary in their subcellular localization and differ in their 
kinetics [72]. Hence, it is necessary to use tools that allow us to gain a better 
understanding of the context in which redox reactions occur. However, 
whole-cell extract based assays can be useful to obtain an overall look and 
determine whether certain conditions are pro-oxidative or reducing at a 
general level, for example, by measuring glutathione; and even though they 
are usually specific, reproducible and sensitive, they do not give any 
information about specific compartments.  
FLUORESCENT PROBES FACILITATE 
MONITORING OF ROS IN CELL CULTURES 
A variety of redox-active fluorescent probes that are triggered by different 
oxidative species are commercially available. They enable monitoring of 
redox processes in the cell through microscopy techniques, and can be 
combined with compartment-specific dyes to increase spatial-specificity of 
the reactions studied. They are easy to use in culture and some of them can 
be used to stain tissues too. The use of general probes, such as 2´,7´-
dihydrodichlorofluorescein (H2DCF), dihydroethidium (DHE), cellROX, 
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dihydrorodamine (DHR) or mitochondria-targeting ones, like mitoSOX or 
mitoPY1, are widely spread in the literature. Though useful, a major caveat is 
their partial non-specific behavior, meaning that they can be triggered by 
several oxidative reactions, and their activation is irreversible, making the 
analysis of redox kinetics impossible.   
GENETICALLY ENCODED BIOSENSORS 
INCREASE SPATIO-TEMPORAL RESOLUTION 
In order to define redox processes in their natural context, genetically 
encoded redox probes based on green fluorescent protein (GFP) were 
developed. In this thesis redox-sensitive GFP (roGFP) biosensors were used, 
but there are other biosensors available, such as redox-sensitive yellow FP 
(rxYFP) and HyPer. Some of the major advantages of roGFP is its ratiometric 
fluorogenic behavior, and the possibility of engineering redox relays between 
redox enzymes and roGFPs to increase its specificity and sensitivity, and equal 
response of the fluorescent protein in different tissues. 
In papers I and II we used biosensors based on enhanced GFP (EGFP) 
developed by Tobias Dick´s lab [73]. Briefly, two reactive cysteines were 
engineered in positions S147 and Q204, located on β-strands 7 and 10 of 
EGP. Excitation maxima from GFP are preserved (400 nm for A-band and 
475-490 nm for B-band), but oxidation results in an increase in excitability in 
the A-band and a decrease in the B-band and a reverse behavior during 
reducing conditions. Analyzing the ratio of fluorescence intensity between 
the 405 and 488 excitation maxima, one can conveniently visualize oxidative 
processes (increased ratio) or reducing reactions (decreased ratio). By fusing 
roGFP with human glutaredoxin-1 (Grx1) real-time equilibration between 
the sensor protein (Grx1-roGFP) and the glutathione redox 
  
couple (GSH/GSSG) is facilitated, [74], and fusion to the yeast peroxidase 
Orp1 mediates oxidation of roGFP by H2O2 [75]. Versions of the probes that 
target specifically to the mitochondrial matrix are also available. 
Figure 3. roGFP2 excitation is dependent upon redox changes (Meyer and Dick, 2010). When 
roGFP is oxidized, the fluorescence intensity increases when excited at 405 nm (blue line). 
When it is reduced, its maximum fluorescence peak appears when excited at 488 nm (red line). 
Increases in the 405/488 fluorescence ratio, indicate an oxidative condition or process. 
  
RATIONALE, RESULTS & DISCUSSION  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trust those who seek the truth, doubt those who found it; doubt everything; but 
don’t doubt yourself. – André Gide  
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RATIONALE 
The overall aim of this thesis was to evaluate the effect of antioxidant 
supplementation in the progression of cancer, with special focus on malignant 
melanoma.  
The specific aims of the two papers included in the thesis were: 
I. Antioxidants can increase melanoma metastasis in mice 
The rationale behind this first paper was to assess the impact of NAC 
and vitamin E as dietary antioxidants on the progression of a 
malignant melanoma mouse model, in order to validate the 
hypothesis that tumors, with high endogenous ROS levels, benefit 
from additional antioxidant supplementation.  
II. Mitochondria-targeted antioxidants do not influence 
malignant melanoma and lung cancer progression in mice  
The aim of this second study was to determine whether targeting 
mitochondria, the main source of cellular ROS, with antioxidant 
compounds would hinder cancer progression in mouse models of 
lung cancer and malignant melanoma.  
  
  
PAPER I: ANTIOXIDANTS CAN INCREASE 
MELANOMA METASTASIS IN MICE 
Following up on a study published by Sayin and colleagues in 2014 [76], we 
decided to investigate whether the accelerated proliferation observed upon 
antioxidant treatment was exclusive to lung cancer or if it could be 
extrapolated to other forms of cancer. 
THE GENERAL ANTIOXIDANTS NAC AND 
VITAMIN E ACCELERATE METASTASIS 
In this study we show that, dietary supplementation of NAC in the drinking 
water doubled the number of lymph metastases in BPT mice [77]. In addition, 
these metastases showed increased S100B and Nestin staining, both markers 
of malignancy [78, 79].   
Concordant to our in vivo observations, NAC and Trolox, an analogue of 
vitamin E, increased migrating and invasive properties in a panel of human 
melanoma cell lines. 
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Figure 4. NAC administration increases metastasis in mice with malignant melanoma. NAC 
was administered in the drinking water to newly weaned BPT mice. Upper panel shows number 
of lymph metastases (left) and surface lung metastases (right). Lower panel shows 
immunochemical detection of S100B and Nestin in lymph metastases. 
  
Figure 5. NAC and Trolox increase migrating and invasive properties of human melanoma 
cells.Real-time analysis of migration (upper panel) and invasion (lower panel) of cell line sk-
mel-28. Right panels show migration and invasion indices at the 10-hour time point from real-
time analyses of these parameters in seven melanoma cell lines incubated with control medium 
or medium supplemented with NAC. 
Follow-up studies revealed that: dietary vitamin E markedly increased the 
number of lymph metastases but not primary tumors in mice, which was in 
agreement with our previous in vitro observations. 
Figure 6. Vitamin E increases metastasis in mice with malignant melanoma. Vitamin E was 
supplemented in the chow diet to newly weaned BPT mice. Left panel shows the number of skin 
tumors and right panel shows the number of lymph metastases. 
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THE INCREASED MIGRATION DEPENDED ON GSH 
SYNTHESIS 
Consequent with NAC supplementation, the levels of GSH were increased, 
but only significantly in the lymph metastases. These results were supported 
by in vitro analyses of GSH/GSSG content of antioxidant treated cell lines, and 
unexpectedly they were also elevated by Trolox. 
Figure 7. Levels of reduced glutathione are increased by antioxidant treatment. Left panel 
shows markedly increased GSH/GSSG ratios in lymph metastases of NAC treated mice. Center 
and right panels show increased GSH/GSSG ratios in human melanoma cells treated with NAC 
or Trolox.  
We then proceeded to investigate whether the increased migration was 
dependent on GSH by inhibiting de novo synthesis of glutathione with 
buthionine sulfoximine (BSO). Indeed, upon BSO treatment migration was 
brought back to baseline, indicating that the increased antioxidant-triggered 
migration depended on GSH. 
  
Figure 8. NAC- and Trolox-triggered migration depends on GSH. Real-time analyses of sk-mel-
28 migration in response to NAC, BSO, and NAC +BSO (left panel) and Trolox, BSO, and 
Trolox + BSO (right panel). 
Next, we looked into the RHO family proteins RHOA and RAC1, which 
mediate cytoskeletal changes during migration and invasion and have been 
shown to be redox regulated [80]. RAC1 oxidation increases its activity and 
promotes lamellipodia formation [81]. In opposition, oxidative stress leads to 
the formation of an intramolecular disulfide bridge in RHOA which prevents 
guanine nucleotide exchange, therefore inactivating the protein. Disulfide 
formation can be reversed by the addition of reductants [82]. Indeed, RHOA 
activity was elevated in antioxidant treated cells and further downstream 
signaling inhibition of Rho-associated protein kinase (ROCK) reverted the 
antioxidant-dependent increased migration. 
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Figure 9. Antioxidant increased migration correlates with elevated levels of active RHOA. 
Human melanoma cells treated with antioxidants show higher levels of GTP-bound RHOA 
(upper and middle panels). The increased migration is reverted when cells are subjected to 
treatment with a ROCK inhibitor (lower panels). 
CANCER PATIENTS AND SURVIVORS SHOULD 
AVOID ANTIOXIDANT SUPPLEMENTS 
In this study we use two different antioxidants with distinct chemical 
structures and properties: NAC which is hydrophilic and can act as a 
precursor of cysteine and glutathione synthesis, and Trolox, which is a soluble 
analogue of the lipophilic peroxyl radical scavenger vitamin E. We additionally 
treated mice with chow diet containing supplementary vitamin E (in the form 
of Dl-α-tocopheryl acetate), although this was not included at the time in the 
publication. In all cases the net result was the same: mice had significantly 
  
more metastases at endpoint, and human malignant melanoma cells migrated 
and invaded more.  
In order to ensure that the doses administered in vivo were in accordance 
to human doses, we used a body surface area conversion [83]. NAC 
supplementation was in range of what it is prescribed to COPD patients and 
vitamin E doses were adjusted to 20 times the recommended daily intake, 
which can be found in vitamin supplements. 
Shortly after the release of this article, other publications showed that 
oxidative stress limits metastasis of human malignant melanoma cells injected 
into immunocompromised mice [84], and it also impairs tumor invasion in 
vivo by suppressing Rho-ROCK activity through mechanisms involving p53 
[85], all of which further supported our findings. Additionally, another group 
reported that several antidiabetic drugs with antioxidant properties 
accelerated metastasis in mouse models of cancer [86].  
Although it remains to be seen whether these results can be directly 
translated into the context of human health care, all of the studies above 
mentioned together with the lack of evidence showing beneficial effects of 
antioxidant supplementation in the vast majority of cancer clinical trials 
suggest that cancer patients and people at risk of developing cancer should 
avoid the use of antioxidant supplementation [29].  
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PAPER II: MITOCHONDRIA-TARGETED 
ANTIOXIDANTS DO NOT INFLUENCE 
MALIGNANT MELANOMA AND LUNG 
CANCER PROGRESSION IN MICE 
Following our observations that dietary antioxidant supplementation 
accelerated proliferation and metastasis in lung cancer and malignant 
melanoma respectively, we decided to target ROS at its main production site. 
Previous studies hypothesize that mitochondria-associated and not cytosolic 
ROS are responsible for the pro-tumorigenic signaling [87-89]. This raises 
the possibility of using mitochondria-targeted antioxidants to inhibit tumor 
growth. 
In order to target mitochondrial ROS we used two different antioxidant 
compounds conjugated to a lipophilic cation, which ensures uptake through 
the phospholipid bilayer and mitochondrial accumulation by plasma 
membrane potential. 
 
  
Figure 10. Chemical structure of the mitochondria-targeted antioxidants used in Paper II. The 
compounds mitoQ and dTPP share the same 10-carbon lipophilic cation moiety, while 
mitoTEMPO has a shorter chain. 
MitoQ is a ubiquinone conjugated to a decyltriphenylphosphonium (dTPP) 
cation [90-92], that is recycled by the ETC. Its main antioxidant function is 
preventing mitochondrial lipid peroxidation [93], although it is also suggested 
that it acts upstream of H2O2 production [94]. MitoTEMPO on the other 
hand, is the combination of the antioxidant piperidine nitroxide with a 
lipophilic cation. It acts as a SOD mimetic and detoxifies O2· [95].  
MITOCHONDRIA-TARGETED ANTIOXIDANTS 
DO NOT INHIBIT CANCER PROGRESSION 
In this study we added mitoQ and its control compound dTPP to the drinking 
water of BPT and lung cancer mice. MitoQ treatment did not increase 
survival nor reduced other parameters of progression such as tumor growth 
or metastasis. Intra-peritoneal injection of mitoTEMPO in BPT mice 
however, reduced survival and accelerated the kinetics of primary tumor 
growth.   
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Figure 11.  Mitochondrial antioxidants do not slow down malignant melanoma progression in 
mice. Upper panels show number of skin tumors, lymph metastases and survival of mice treated 
with mitoQ, dTPP and water controls. Lower panels show number of skin tumors, lymph 
metastases and survival of mice injected with mitoTEMPO, PBS or controls. 
Figure 12. MitoQ does not decrease tumor burden in a mouse model of lung cancer. Left panel 
shows proliferation index in tumors, central panel shows tumor burden per mouse and right 
panel shows hematoxylin and eosin staining of mouse lungs. 
In vitro results indicate that mitoQ and dTPP disrupt the ETC and affect tumor 
cell proliferation. As these effects are achieved by both substances, we 
hypothesize that they are due to non-antioxidant related cytotoxic effects. 
Indeed, accumulation of lipophilic cations in the mitochondrial matrix surface 
  
of the inner membrane can disrupt membrane permeability and affect 
enzymatic transporter activity [96-98]. 
Figure 13. MitoQ effects on proliferation and ETC are non-antioxidant related. Upper panels 
show proliferation of mitochondria-targeted antioxidant-treated human melanoma cells over a 
course of 48hours. Lower panels show the effects on the extracellular acidification rate (ECAR) 
and oxygen consumption rate (OCR) of mitochondria targeted antioxidants on human 
melanoma cells. 
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Figure 14. The mitochondria-targeting cation dTPP disrupts proliferation and ETC in human 
lung cancer cells. Upper panels show proliferation of mitochondria-targeted antioxidant-
treated human lung cancer cells. Lower panels show the effects of antioxidant treatment on the 
extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) in human lung 
cancer cells. 
In addition, treatment of human melanoma cells with antioxidants show 
significant hyperpolarization of the mitochondria at the concentrations used 
during proliferation assays as indicated by JC-1 staining. Furthermore, 
increases in membrane potential are associated with a lower respiration rate 
and increased ROS production at complexes I and III of the ETC [99-101], 
indicating that the accumulation of the compound in the mitochondria might 
render an effect opposite to the one desired.  
 
  
Figure 15. Accumulation of JC-1 aggregates in the mitochondria of antioxidant-treated human 
melanoma cells and melanocytes. Upper panel shows the mean of 4 different melanoma cell 
lines with 3 wells per treatment and cell line and 15 fields of view per well. Lower panel shows 
the mean of human C4 melanocyte with 3 wells per condition and 15 fields of view per well. 
Increases in aggregates indicate higher mitochondrial membrane polarization. 
Interestingly, oxygen consumption was not affected by mitochondria-targeted 
antioxidants in lung cancer cells, and only mitoQ but not mitoTEMPO 
affected it in melanoma cells.  
To look at the possibility that mitochondria-targeted antioxidants might 
increase ROS production, we used different genetically encoded biosensors 
in human melanoma cells. We found that cytosolic oxidation was increased 
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at basal levels after 48 hours of treatment with mitoTEMPO in both cell lines 
assayed. 
Figure 16. Ratio of cytosolic glutathion oxidation/reduction in human melanoma cells assessed 
with a Grx1-roGFP2 biosensor. Red arrows indicate addition of diamide to induce further 
oxidation. Incubation of cells with 100 nM mitoTEMPO for 48 hours induced cytosolic 
oxidation in both cell lines. 
  
MITO-TEMPO INCREASES CYTOSOLIC OXIDATION 
Our results suggest that by acting as a SOD mimetic, mitoTEMPO might 
detoxify O2· to H2O2 which can then diffuse to the cytosol where it can act 
as a signaling pathway regulator. In order to look further into the role of 
mitoTEMPO as a ROS scavenger, we used genetically encoded biosensors to 
look into differences in H2O2 content in the mitochondria of human 
melanoma cells. 
Figure 17. Ratio of mitochondrial oxidation assessed with the H2O2- sensitive Orp1-roGFP2 
biosensor in human melanoma cells. Red arrows indicate addition of diamide to induce further 
oxidation. Incubation of cells with 100 nM mitoTEMPO and dTPP for 48 hours induced 
mitochondrial oxidation in both cell lines. 
Additionally, gene expression analysis of primary tumors from mitoTEMPO 
–treated mice showed increased expression of Krt1, Alb, Gpx2, Duox1, Ucp3, 
Mb and Hspa1a when compared to their control counterparts. Although 
indirectly, these gene expression changes indicate a response to increased 
ROS levels; Keratin 1 (Krt1) levels have been shown to increase under H2O2 
stimulation [102], albumin (Alb) is a reported oxygen scavenger in vivo [103, 
104], glutathione peroxidase 2 (Gpx2) is a H2O2-reducing enzyme that has 
been linked to increased metastasis [105, 106], and the uncoupling protein 3 
(Ucp3) can mildly uncouple the ETC to reduce mitochondrial ROS levels 
[107-110]. Myoglobin (Mb) is inactivated at protein level by oxidation, 
although it has also been reported to propagate oxidation by interacting with 
hydrogen peroxide, and the increased transcriptional levels observed might 
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be a compensatory mechanism to such protein inhibition [111, 112]. The heat 
shock protein family A member 1A (Hspa1a) has been reported to participate 
in the removal of proteins damaged by oxidation [113]. Interestingly, the 
H2O2 producing dual oxidase 1 (Duox1) was also overexpressed. This result 
is in opposition to what Dikalov and colleagues have previously described on 
how blocking mitochondrial O2· production with mitoTEMPO 
downregulated cytosolic O2· production by NOXes, breaking a forward feed 
loop [114]. 
Overall we conclude that mitoTEMPO acts as a mitochondrial 
antioxidant/cytosolic pro-oxidant in our system. To validate such hypothesis 
we could isolate mitochondria and look at excreted H2O2 upon mitoTEMPO 
treatment. If our hypothesis was confirmed, we could conditionally 
overexpress catalase in human melanoma cells in vitro or in BPT mice in vivo 
to see whether the phenotypes observed can be reverted. 
MITOCHONDRIA-TARGETED ANTIOXIDANTS: 
THESE ARE NOT THE COMPOUNDS YOU ARE 
LOOKING FOR 
Previous studies have shown that mitochondria-targeted antioxidants could 
potentially inhibit tumor development. Indeed, combined inhibition of 
mitochondrial ROS and glycolysis successfully decreased ATP production and 
induced apoptosis in hepatocellular carcinoma [30]; targeting mitochondrial 
ROS decreased KRAS-mediated tumorigenicity by increasing ERK 1/2 
signaling [32]: it also reversed superoxide-dependent migration upon partial 
ETC inhibition [31]. 
Although promising, none of these studies have evaluated the impact of such 
compounds in transgenic mouse models. Even with similar doses, neither 
mitoQ nor mitoTEMPO blocked disease progression. In fact, mitoTEMPO 
  
decreased survival which is in concordance with the work of Wang and 
colleagues, where mitochondria-targeted antioxidants aggravated 
tumorigenesis by affecting DNA-damage repair in a chemically induced model 
of hepatocellular carcinoma [86].   
In addition, our in vitro results show that no direct translation can be drawn 
to an in vivo context, which might explain the conflict with previous studies. 
Furthermore, the effects observed with mitoQ treatment were recapitulated 
by the control substance, suggesting that the decrease in proliferation 
observed is related to cytotoxic effects coupled to the targeting moiety 
rather than to antioxidant properties of the ubiquinone. It has been proposed 
that genetic therapy with alternative oxidase, an enzyme present in plants and 
lower animals, could potentially reduce mitochondrial ROS formation by 
bypassing the ETC when disrupted and maintaining the electron flow and 
redox homeostasis in the cell [115, 116]. However, preliminary histological 
data indicates that the ETC complexes remain unaltered in the mitochondria-
targeted antioxidant-treated mice, questioning the usefulness of such 
treatment in our model (data not shown). 
Mitochondrial antioxidants have been successfully used in other areas and 
models, such as in acute hypoxia, inflammation, cardiovascular diseases, and 
ischemia reperfusion [117-120], but our results demonstrate that they are 
unlikely to be useful in cancer therapy.  
 
 
  
GENERAL DISCUSSION 
& 
FUTURE WORK 
 
 
 
 
 
 
 
 
 
 
 
 
One never notices what has been done; one can only see what remains to be 
done. – Marie Sklodowska-Curie 
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THE ANTIOXIDANT/ROS DOGMA NEEDS 
TO BE RECONSIDERED 
ROS are not only damaging products, they are important players in the 
maintenance of cell signaling and homeostasis. 
Antioxidant supplementation has been traditionally seen as a way to protect 
against oxidative stress-related damage. However, antioxidants protect both 
healthy and tumor cells. The latter have elevated levels of ROS and rely on 
antioxidant defenses to protect themselves from further damage. 
Antioxidants give them the additional help they need. 
In paper I we show that general antioxidants supplied in the diet accelerate 
metastasis in in vivo and in vitro models of malignant melanoma. 
In paper II we show that mitochondria-targeted antioxidants did not inhibit 
cancer progression in vivo. In fact, one of the compounds, mitoTEMPO, 
reduced survival of mice with malignant melanoma and this was accompanied 
by increased levels of cytosolic H2O2. 
ARE HYPOTHETICAL BENEFITS OF 
ANTIOXIDANTS WORTH THE RISK? 
Clinical trials have consistently failed at showing the value of antioxidant 
supplementation for the prevention and treatment of cancer. In fact, meta-
analysis studies of clinical trials show that antioxidant supplementation lacks 
support for beneficial effects and may increase mortality of certain forms of 
cancer [121-124]. 
In addition, there is a widespread use of antioxidant supplements by cancer 
patients [125-128] partially to alleviate toxic radiotherapy and chemotherapy 
side-effects, but also prompted by the popular conception that antioxidants 
help fighting cancer. Interestingly, the published literature suggests growing 
 concern and debate amongst clinicians on the potential interference of such 
supplements with therapy that relies on the production of ROS and induction 
of apoptosis [129-133]. 
Furthermore, although some experimental studies of chemically- and 
radiation-induced cancers have displayed potential therapeutic effects of the 
use of antioxidants [134, 135], there is an increasing body of evidence 
showing their role in the acceleration of progression [136-138].  
Overall, there is no doubt that redox regulation plays an important role in 
the development and progression of cancer. We therefore think that the 
study of redox-regulated pathways, proteins and genes might reveal new drug 
targets and offer new and reliable therapeutic possibilities [139].  
FUTURE WORK 
One of the main difficulties in the field is the study of redox reactions in vivo. 
Indeed, we have to rely on methods that can give an overall idea of whether 
certain conditions are pro-oxidative or reductive. As described in the 
methods section, the use of genetic encoded biosensors has revolutionized 
the field by giving the possibility to analyze when and where in the cell these 
redox reactions occur. This tool is now being expanded to in vivo models in 
Tobias Dick´s group, where genetically encoded biosensors have been stably 
expressed in mouse tissues [140]. This opens many possibilities if combined 
with our cancer models, since it would be easier to pinpoint where and when 
during the development of the disease redox alterations occur with and 
without the use of antioxidants.  
For instance, in Paper I we saw that the increased migrating and invasive 
properties of cancer cells were dependent on new synthesis of GSH [141]. 
We also saw that the GSH/GSSG ratio was increased in lymph metastases of 
NAC treated mice according to a whole cell extract assay. It would be 
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interesting to combine the BPT model with the expression of a glutathione 
biosensor to observe whether this increase is particular to the cells that 
survive transit from the primary tumor to the lymph nodes, or whether it is 
only those cells within the primary tumor that show increased GSH that 
migrate.  It would also allow us to see what happens with the rest of the cells 
in the neoplastic niche. For instance, it is well known that redox regulation 
plays an important role in the vascularization of tissue. It has been proposed 
that low levels of ROS can stimulate angiogenesis and therefore influence 
tumor progression [142]. Indeed, the accelerated growth kinetics observed 
in mitoTEMPO-treated mice might be related not so much to tumor cell 
proliferation in itself as to a better vascularization of the neoplastic tissue, 
prompted by the excretion of H2O2. 
Another important point from Paper I was that migration was also dependent 
on RHOA signaling, and we hypothesize that this increase in signaling is due 
to either the inhibition by reduction of RAC1 (and hence de-repression of 
RHOA) or activation of RHOA by reduction. But we cannot rule out other 
effects of redox regulation of the cytoskeleton. One way of analyzing this 
would be to study the thiol proteome by mass spectrometry and study 
potentially GSH-regulated cysteines.  
We could combine these results with RNAseq analysis of primary tumors 
and lymph metastases from NAC and vitamin E treated mice, to get a better 
landscape of redox regulation by antioxidant supplementation. Although the 
phenotype exhibited by both treatments is the same, we cannot rule out that 
the underlying mechanisms are different. 
To that end, it would be interesting to perform the same experiments in 
immunodeficient mice to rule out the possibility that effects on the immune 
system are responsible for the observed metastasis.  
 In Paper II we observed a decreased survival by mitoTEMPO and we argue 
that growth kinetics were affected by the treatment. To challenge this idea, 
we are now repeating a new study where mice will be sacrificed after five 
weeks of treatment. We also observed that scavenging of mitochondrial O2· 
resulted in increased levels of cytosolic ROS and we hypothesize that this in 
turn triggers cellular signaling cascades that accelerate growth. To verify the 
hypothesis we could overexpress a mitochondrial catalase to decrease pro-
tumorigenic signaling from mitochondrial H2O2 or isolate mitochondria and 
measure H2O2 excretion. 
In addition to these studies, we are interested in comparing different methods 
of antioxidant delivery to the skin in the context of malignant melanoma. Skin 
lotions often contain different forms of antioxidants, whether with the 
purpose of stabilizing formulation and avoiding rancidity or with the promise 
of improving skin texture and condition. We are interested in studying how 
these will affect malignant melanoma progression. I have administered vitamin 
E in the diet, and as a lotion to BPT mice, and I am going to test dietary 
mitochondrial targeting with mitoE.  
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